bm|t beteiligungsmanagement thüringen gmbh is securing the finances of SIRS-Lab GmbH in Jena with a further injection of capital and in so doing, increasing its share in the high-tech company to 49 percent. In this way, SIRS-Lab is being provided with the financial scope to proceed with its planned developments and introduce new products on the market.
Products for Sepsis Diagnosis
SIRS-Lab develops and produces diagnostic aids for the early diagnosis and therapeutic control of sepsis-related ailments. Approximately 150,000 people fall victim to sepsis – also popularly known as blood poisoning – every year in Germany, about half of whom die. The founders of SIRS-Lab GmbH are internationally recognised research scientists and clinicians with special expertise in intensive medicine.
At present, the company is already marketing biochips for academic research and for use in the pharmaceutical industry. Its new products are aimed particularly at clinics. SIRS-Lab was founded in the year 2000 and employs 26 staff. The company will be exhibiting at the “Bio” biotechnology fair in Philadelphia, USA, from the 19th to the 21st June, which is the world’s largest fair of its kind.
Dr. Stefan Rußwurm
Winzerlaer Str. 2
+49 (0) 3641 508–430
+49 (0) 3641 508–432